Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients with Breast Cancer at High Risk of Recurrence
Scientific Rationale for the study design: Copper depletion is designed to be a complement to standard therapy to overcome resistance mechanisms hence it would be optimal to combine it with standard adjuvant therapy which at the current time is capecitabine and pembrolizumab.Study Design:Phase 1b: Patients with triple negative breast cancer who have completed standard neoadjuvant therapy (chemotherapy + pembrolizumab) and who have residual disease at RCB 2, 3 will start adjuvant therapy with standard dose capecitabine, standard dose pembrolizumab and tetrathiomolybdate (TM). Patients must have received neoadjuvant immunotherapy (pembrolizumab) and wish to continue adjuvant immunotherapy for at least one cycle on trial. The capecitabine will be for 6 months with concurrent TM and TM will continue for an additional 2.5 years (for a total of 3 years of treatment). Patients must stay on immunotherapy for at least the first cycle of the study and subsequently as per physician's choice.This phase of the study is designed to assess safety of TM with capecitabine + immunotherapy (pembrolizumab) as adjuvant therapy for TNBC.With a standard 3+3 design, the maximum possible total number of patients is 18.Randomized Phase 2: Patients with triple negative breast cancer who have completed standard neoadjuvant therapy (chemotherapy +/- pembrolizumab) and who have residual disease at RCB 2, 3 will start adjuvant therapy with standard dose capecitabine or capecitabine and tetrathiomolybdate (TM). If they received neoadjuvant pembrolizumab and wish to continue adjuvant immunotherapy, they may continue. The capecitabine will be for 6 months with concurrent TM and TM will continue for an additional 2.5 years (for a total of 3 years of treatment). If they elect to continue immunotherapy, then they should complete one year total or as per physician's choice.Patients will be randomized with a 1:1 allocation ratio between the two treatment arms.There will be at most 186 patients accrued to account for 10% loss to follow-up over the course of the approximately 5-year study period.
Novelty and Early Assessment of Temperament (NEAT) Study
This pilot study will examine individual differences in how the brain processes novelty. This will provide preliminary data on the neural mechanisms that underlie attention to novelty, a key behavioral risk marker of anxiety disorders.
NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I HORMONE SENSITIVE HER2-NEGATIVE ONCOTYPE RECURRENCE SCORE = 18 BREAST CANCER
Primary ObjectiveTo evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of ipsilateral-breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.Primary HypothesisBreast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral-breast tumor recurrence (IBTR) as compared to breast conservation, breast radiation, and endocrine therapy.
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1 ER Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)
This study wants to see if giving extra chemotherapy (adjuvant chemotherapy (ACT) to ovarian function suppression plus endocrine therapy) helps premenopausal women with early-stage breast cancer. The study team wants to know if adding this extra treatment (ACT) can improve survival rates and keep the cancer from coming back. The study team is also checking if the extra treatment causes more menopausal symptoms or more pain during other treatments. Additionally, they'll look at how well patients stick to their treatment plan, the effect on their ovaries, any long-term side effects, and how their quality of life is affected.
NRG-GI011 A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
NTM Patient Education Program | NYU Langone Health
People who have nontuberculous mycobacterial infections are invited to an education program hosted by NYU Langone.
Nuclear Medicine Imaging | NYU Langone Health
NYU Langone offers nuclear medicine imaging, which uses a small quantity of radioactive material to diagnose diseases.
Nursing at NYU Langone | NYU Langone Health
NYU Langone’s nationally recognized nurses are committed to providing world-class care and improving patient outcomes.
Nursing at NYU Langone Hospital—Brooklyn | NYU Langone Health
The nurses at NYU Langone Hospital—Brooklyn work together to provide safe, quality care to our patients.
Nursing at NYU Langone Hospital—Long Island | NYU Langone Health
Nurses at NYU Langone Hospital—Long Island are dedicated to keeping patients safe while delivering the highest level of care.